Walker Neal
SEC insider (Form 3/4/5 filer). CIK 0001604457. Director at Aldeyra Therapeutics, Inc. (ALDX) and 1 other issuer. 35 reported Form 4/5 transactions since Sep 2024; latest on Jun 9, 2026. Located in LEXINGTON, MA.
Companies Walker Neal has filed insider reports for
- Aldeyra Therapeutics, Inc. (ALDX): Director
- Aclaris Therapeutics, Inc. (ACRS): Director, Officer, CEO
Walker Neal
CIK: 0001604457
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (35 total)
- Jun 9, 2026ALDX
Aldeyra Therapeutics, Inc.
AwardDirectStock Option (Right to Buy)
70K shares- - Jun 9, 2026ALDX
Aldeyra Therapeutics, Inc.
AwardDirectStock Option (Right to Buy)
3.3K shares- - Feb 3, 2026ACRS
Aclaris Therapeutics, Inc.
ExerciseDirect63.5K shares- - Feb 3, 2026ACRS
Aclaris Therapeutics, Inc.
Tax PaymentDirect18.6K shares at avg. $3.47$65K - Feb 2, 2026ACRS
Aclaris Therapeutics, Inc.
AwardDirectEmployee Stock Option (Right to Buy)
961.7K shares- - Feb 2, 2026ACRS
Aclaris Therapeutics, Inc.
AwardDirectRestricted Stock Units
274.8K shares- - Jan 2, 2026ACRS
Aclaris Therapeutics, Inc.
ExerciseDirect29.2K shares- - Jan 2, 2026ACRS
Aclaris Therapeutics, Inc.
Tax PaymentDirect10K shares at avg. $2.88$29K - Jun 10, 2025ALDX
Aldeyra Therapeutics, Inc.
AwardDirectStock Option (Right to Buy)
62.7K shares- - Jun 10, 2025ALDX
Aldeyra Therapeutics, Inc.
AwardDirectStock Option (Right to Buy)
2.4K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jun 9, 2026 |  ALDX Aldeyra Therapeutics, Inc. | Award Stock Option (Right to Buy) | 70,000 | - | - | Direct |
| Jun 9, 2026 | ALDX Aldeyra Therapeutics, Inc. | Award Stock Option (Right to Buy) | 3,318 | - | - | Direct |
| Feb 3, 2026 |  ACRS Aclaris Therapeutics, Inc. | Exercise | 63,475 | - | $0 | Direct |
| Feb 3, 2026 | ACRS Aclaris Therapeutics, Inc. | Tax Payment | 18,611 | $3.47 | $64,580 | Direct |
| Feb 2, 2026 | ACRS Aclaris Therapeutics, Inc. | Award Employee Stock Option (Right to Buy) | 961,700 | - | - | Direct |
| Feb 2, 2026 | ACRS Aclaris Therapeutics, Inc. | Award Restricted Stock Units | 274,800 | - | - | Direct |
| Jan 2, 2026 | ACRS Aclaris Therapeutics, Inc. | Exercise | 29,150 | - | $0 | Direct |
| Jan 2, 2026 | ACRS Aclaris Therapeutics, Inc. | Tax Payment | 9,952 | $2.88 | $28,662 | Direct |
| Jun 10, 2025 | ALDX Aldeyra Therapeutics, Inc. | Award Stock Option (Right to Buy) | 62,728 | - | - | Direct |
| Jun 10, 2025 | ALDX Aldeyra Therapeutics, Inc. | Award Stock Option (Right to Buy) | 2,413 | - | - | Direct |
1-10 of 35 transactions